Manufacturing

Articles

Three companies joined the University of Pittsburgh Medical Center's 21st Century Biodefense initiative to establish a flexible vaccine development and production facility.

Companies Join University Project to Build Vaccine Facility

The US Food and Drug Administration recently published guidance for the characterization and qualification of cell substrates, viral seeds, and other biological materials used to manufacture viral vaccines for human use.

FDA Issues Guidance for Manufacturing Cell-Based Viral Vaccines

Hoping to prevent the deaths of eight million children over the next decade, Bill and Melinda Gates recently committed $10 billion for child-immunization programs in the world's poorest countries.

Gates Foundation Pledges $10 Billion for Vaccines

Jill Wechsler is Pharmaceutical Technology's Washington Editor, jillwechsler7@gmail.com.

Vaccine R&D is surging, but continues to raise manufacturing and regulatory challenges.

Manufacturers Look to Vaccines for Growth and Innovation

Stephanie Sutton was an assistant editor at Pharmaceutical Technology Europe.

Pharmaceutical Technology Europe discusses some of the latest challenges and innovations that are expected to define the future of pharma.

Biopharmaceuticals: saving the future of our industry

The vaccine sector is challenging for both R&D and manufacturing because a wide variety of technologies and techniques are required &#151; even the largest companies find it difficult to cover all the relevant areas of expertise &#151; and this drives up development costs and often forces companies into multiple collaborations to obtain the required expertise and technologies.

Disposables help overcome some challenges of vaccine manufacture

Influenza vaccines can be produced faster using a new insect cell-based technology compared with traditional egg-based processes, according to scientists in Vienna (Austria).

Insect cells offer faster flu vaccines

GlaxoSmithKline (GSK) has agreed to donate 50 million doses of its adjuvanted pandemic influenza A (H1N1) vaccine to the World Health Organization (WHO).

GSK donates flu vaccine to the WHO

Last week, GlaxoSmithKline (GSK, London) agreed to donate 50 million doses of its adjuvanted pandemic influenza A (H1N1) vaccine to the World Health Organization (WHO).

GSK Donates Influenza A (H1N1) Vaccine to WHO

Company and People Notes: Genzyme provides updates on enzyme replacement products and FDA complete response letter; Watson appoints VP of global operations; more...

Manufacturing, Biologic Drugs